Arrowstreet Capital, Limited Partnership Atara Biotherapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $1.6 Million - $4.91 Million	562,886 Added 354.63%	721,609 $2.73 Million
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $543,711 - $1.14 Million	115,930 Added 270.91%	158,723 $1.24 Million
Q1 2022 May 13, 2022	BUY	$8.44 - $16.89 $361,172 - $722,773	42,793 New	42,793 $398,000
Q1 2021 May 14, 2021	SELL	$14.0 - $20.72 $1.22 Million - $1.8 Million	-87,113 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$12.67 - $26.23 $558,911 - $1.16 Million	44,113 Added 102.59%	87,113 $1.71 Million

Q3 2020 Nov 12, 2020	BUY	$11.92 - $15.87 $512,560 - $682,410	43,000 New	43,000 $557,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.